

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-A**

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Kairos Pharma, Ltd.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation or organization)

**46-2993314**

(I.R.S. Employer  
Identification No.)

**2355 Westwood Blvd., #139**

**Los Angeles**

(Address of principal executive offices)

**90064**

(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class  
to be so registered

**Common Stock, par value \$0.001 per share**

Name of each exchange on which  
each class is to be registered

**The NYSE American LLC**

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box.

If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box.

If this Form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-274805

Securities to be registered pursuant to Section 12(g) of the Act: **None**

## INFORMATION REQUIRED IN REGISTRATION STATEMENT

### **Item 1. Description of the Registrant's Securities to be Registered.**

A description of the common stock, par value \$0.001 per share, of Kairos Pharma, Ltd., a Delaware corporation (the "Registrant"), to be registered hereunder is set forth under the heading "Description of Capital Stock" in the prospectus constituting a part of the Registrant's Registration Statement on Form S-1 (File No. 333-274805), originally filed with the Securities and Exchange Commission (the "Commission") on September 29, 2023, as subsequently amended, and is incorporated herein by reference. The description of the common stock included in any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Section 424(b) of the Securities Act of 1933, as amended, shall also be deemed to be incorporated herein by reference.

### **Item 2. Exhibits.**

Pursuant to the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on the NYSE American LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Dated: September 12, 2024

Kairos Pharma, Ltd.

By: /s/ John S. Yu

John S. Yu  
Chief Executive Officer